Sign In
Buy EGRX
$0.460
+0 (+0%)
At Close: Jun 03, 2026
Correcting & Replacing: Eagle Pharmaceuticals Reports Third Quarter 2022 Results
11:50am, Wednesday, 09'th Nov 2022 GlobeNewswire Inc.
WOODCLIFF LAKE, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. is re-issuing in its entirety its earnings press release for the third quarter ended September 30, 2022, originall
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
10:00am, Tuesday, 08'th Nov 2022 Benzinga
Gainers
Digital World Acquisition Corp. (NASDAQ: DWAC) shares jumped 66.5% to settle at $29.10 on Monday amid recent reports suggesting Donald Trump could announce a 2024 presidential run this week.
Spirit AeroSystems, Oyster Point Pharma, Snap And Other Big Gainers From Monday
07:00am, Tuesday, 08'th Nov 2022 Benzinga
U.S. stocks closed higher on Monday, with the Dow Jones surging more than 400 points. Here is the list of some big stocks recording gains in the previous session.
Digital World Acquisition Corp. (NAS
Why Oyster Point Pharma Shares Are Trading Higher By Around 40%? Here Are 49 Stocks Moving In Monday's Mid-Day Session
05:46pm, Monday, 07'th Nov 2022 Benzinga
Gainers
Dragon Victory International Limited (NASDAQ: LYL) surged 52.2% to $0.6870.
Veru Inc. (NASDAQ: VERU) shares jumped 47% to $15.22 following publication of briefing documents ahead of the Nov.
Eagle Pharmaceuticals, Inc. (EGRX) Q3 2022 Earnings Call Transcript
02:35pm, Monday, 07'th Nov 2022
Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX ) Q3 2022 Earnings Conference Call November 7, 2022 8:30 AM ET Company Participants Lisa Wilson - Investor Relations Scott Tarriff - President & Chief Executiv
Eagle Pharmaceuticals Reports Third Quarter 2022 Results
11:50am, Monday, 07'th Nov 2022 GlobeNewswire Inc.
WOODCLIFF LAKE, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and nine months
Eagle Pharmaceuticals (EGRX) Q3 Earnings and Revenues Beat Estimates
09:50am, Monday, 07'th Nov 2022
Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 33.33% and 11.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the sto
Is Eagle Pharmaceuticals (EGRX) Stock Undervalued Right Now?
11:21am, Thursday, 03'rd Nov 2022
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Eagle Pharmaceuticals to Host Third Quarter 2022 Financial Results on November 7, 2022
10:50am, Monday, 31'st Oct 2022 GlobeNewswire Inc.
WOODCLIFF LAKE, N.J., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2022 third qua
Eagle Pharmaceuticals to Host Third Quarter 2022 Financial Results on November 7, 2022
06:50am, Monday, 31'st Oct 2022
WOODCLIFF LAKE, N.J., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2022 third quart
SAVE THE DATE: Eagle Pharmaceuticals to Host Investor Day on Tuesday, December 6, 2022, at the Lotte New York Palace Hotel
08:39pm, Wednesday, 19'th Oct 2022 GlobeNewswire Inc.
WOODCLIFF LAKE, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the Company will host an Investor Day on Tu
Eagle Pharmaceuticals Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Treatment of Severe Community-Acquired Bacterial Pneumonia
10:50am, Wednesday, 12'th Oct 2022 GlobeNewswire Inc.
-- Company plans to commence an adequately powered Phase 2 study with approximately 276 patients with severe community-acquired pneumonia at 120 sites worldwide with patient enrollment expected as ear
-- ENA-001, with a novel mechanism of action as an agnostic respiratory stimulant, has previously been granted Rare Pediatric Disease Designation for the treatment of Apnea of Prematurity by the FDA w
Eagle Pharmaceuticals and Enalare Therapeutics Announce Additional Award Worth Up to $50 Million from BARDA to Advance an Intramuscular (“IM”) Formulation of ENA-001
10:50am, Tuesday, 27'th Sep 2022 GlobeNewswire Inc.
-- ENA-001, a new chemical entity with a unique mechanism of action, is being developed as an agnostic respiratory stimulant for use in multiple patient populations experiencing acute respiratory depr
New Strong Sell Stocks for September 26th
12:06pm, Monday, 26'th Sep 2022 Zacks Investment Research
EGRX, ACCO and ATUS have been added to the Zacks Rank #5 (Strong Sell) List on September 26, 2022.
